Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

Sumanta Kumar Pal, MD, FASCO, discusses key biomarker analyses in renal cell carcinoma that will be presented at the 2024 ASCO Annual Meeting.

Dr Pal Previews ASCO 2024 Data in Renal Cell Carcinoma

Most women who attempted to conceive following treatment for stage I to III breast cancer were able to become pregnant at least once.

Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth

Patients under the age of 40 who received HPV vaccines were associated with lower rates of HPV-related cancer vs unvaccinated patients.

HPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age

An artificial intelligence-based navigation tool may be used to call patients who previously missed their colonoscopy appointment with the goal that they will reschedule and attend the new appointment. 

AI Virtual Navigation May Reengage Patients to Undergo Missed Colonoscopies 

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Articles

Sanjal Desai, MD, discusses the feasibility of venetoclax rechallenge following progression on BTK inhibitors in chronic lymphocytic leukemia. 

Desai Details Efforts Exploring Treatment Strategies in CLL Post–BTK Inhibitor Progression

Sarah ES Leary, MD, MS, details the significance of the FDA-approval of tovorafenib for patients with relapsed or refractory BRAF-positive pediatric low-grade glioma. 

Tovorafenib Offers an Efficacious Option for R/R BRAF-Positive Pediatric Low-Grade Glioma 

James Knight, MD, discusses a case study of a patient with brain metastases from prostate cancer and the importance of multidisciplinary, comprehensive care.   

Broadening Differentials in Brain-Metastatic Prostate Cancer Broadens Diagnostic Horizons

Sameer Patel, MD, FACS, of Fox Chase Cancer Center, was recently named Vice President of the Robert H. Ivy Society of Plastic Surgeons. 

Fox Chase Cancer Center’s Dr. Sameer Patel Named Vice President of the Robert H. Ivy Society of Plastic Surgeons

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

The Evolving Treatment Landscape in Light Chain Amyloidosis with Cardiac Involvement

Treatment Approaches in AL Amyloidosis 

Videos

Expert oncologists discuss the current treatment landscape and latest data in the treatment of patients with AL amyloidosis with cardiac involvement.

Expert oncologists Dr. Jeffrey Zonder and Dr. Shaji Kumar discuss AL amyloidosis background, typical patient profiles, and disease staging and risk stratification.

AL Amyloidosis: Background, Patient Profile, and Staging

Dr. Kumar discusses best practices for accurately and prompt diagnosing AL amyloidosis as well as navigating differential diagnosis.

Navigating the Differential Diagnosis of AL Amyloidosis

Dr. Zonder discusses the current treatment landscape in AL amyloidosis, highlighting recent advances.

Expert oncologist Dr. Kumar provides his assessment of unmet needs in AL Amyloidosis, particularly patients with cardiac involvement.

Limitations of Available Treatment Options for Patients with Cardiac Involvement 

Drs. Kumar and Zonder discuss results from the Phase III Vital trial investigating birtamimab and key takeaways.

Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial

Dr. Zonder discusses the safety profile of birtamimab in the VITAL study and the clinical implications.

Birtamimab Safety Profile in the VITAL Study

Dr. Kumar discusses strategies for managing adverse events in patients with AL amyloidosis.

Adverse Event Management in AL Amyloidosis

Dr. Kumar and Dr. Zonder discuss the ongoing confirmatory Phase III AFFIRM-AL trial investigating the efficacy and safety of birtamimab and ongoing recruitment in the trial.

Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment

Expert oncologists discuss the progression treatment landscape in AL amyloidosis and agents of investigation.

Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches

Dr. Zonder and Dr. Kumar share their clinical pearls and perspectives on future directions in the treatment of AL amyloidosis.

Clinical Pearls and Future Directions in AL Amyloidosis

Insights Video Series

Treatment Approaches in AL Amyloidosis

EP: 1.AL Amyloidosis: Background, Patient Profile, and Staging

EP: 2.Navigating the Differential Diagnosis of AL Amyloidosis

EP: 3.Treatment Approaches in AL Amyloidosis

EP: 4.Limitations of Available Treatment Options for Patients with Cardiac Involvement

EP: 5.Birtamimab in AL Amyloidosis: Key Takeaways from the Phase III VITAL Trial

EP: 6.Birtamimab Safety Profile in the VITAL Study

EP: 7.Adverse Event Management in AL Amyloidosis

EP: 8.Ongoing AFFIRM-AL Trial Background, Patient Eligibility, and Active Enrollment

EP: 9.Revolutionizing the AL Amyloidosis Treatment Paradigm: Novel Agents and Combination Approaches

EP: 10.Clinical Pearls and Future Directions in AL Amyloidosis

Latest Conference Coverage